Skip to main content
Premium Trial:

Request an Annual Quote

Roche Point-of-Care Flu/RSV Test Gets 510(k) Clearance, CLIA Waiver

NEW YORK (GenomeWeb) – Roche announced today it has received 510(k) clearance from the US Food and Drug Administration as well as CLIA waiver for a point-of-care molecular test to detect and distinguish influenza A, influenza B, and respiratory syncytial virus.

The 20-minute Cobas Influenza A/B & RSV test runs on Roche's Liat system, a rapid PCR-based platform that currently also runs waived assays for Group A Strep and flu A/B alone.

"For young children and the elderly, it is essential to have a differential diagnosis for RSV and flu to ensure appropriate treatment within a short time frame after symptoms strike," Uwe Oberlaender, Roche's head of molecular diagnostics noted in a statement. The Influenza A/B & RSV test has been validated on 40 common flu strains and seven strains of RSV, the firm said.

Roche's flu A/B test was shown last year to impact patient care, while a flu A/B, RSV test from Cepheid was cleared and waived in December. 

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.